Safinamide Mesylate
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 500mg | $250 | In Stock |
| 1g | $430 | In Stock |
| 5g | $1090 | In Stock |
: Cat #: V0901 CAS #: 202825-46-5 Purity ≥ 98%
Description: Safinamide Mesylate (formerly PNU-151774E, FCE-28073; NW-1015; EMD-1195686; Xadago), the mesylate salt of Safinamide, is a selective and reversible inhibitor of MAO-B with anti-PD (Parkinson's diseas) effects.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 398.45 |
|---|---|
| Molecular Formula | C17H19FN2O2.CH4O3S |
| CAS No. | 202825-46-5 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 80 mg/mL (200.8 mM)r |
| Water: 80 mg/mL (200.8 mM)r | |
| Ethanol: 13 mg/mL (32.62 mM) | |
| Solubility In Vivo | Saline: 30 mg/mL |
| SMILES Code | C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O.CS(=O)(O)=O |
| Synonyms | PNU-151774E, FCE28073; Safinamide mesylate; Xadago; NW 1015; PNU 151774E; EMD 1195686; FCE-28073; Safinamide mesilate; FCE 28073; NW1015; NW-1015; EMD-1195686; EMD1195686; PNU-151774E; Chemical Name: (S)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide methanesulfonate SMILES Code: C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O.CS(=O)(O)=O |
| Protocol | In Vitro | Safinamide mesylate (1-300 µM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When currents are stimulated to a Vtest of +10 mV from a Vh of -110 mV, the IC50 value was 262 µM. When the holding potential is depolarized to -53 mV, the inhibitory effect of Safinamide mesylate with a lower IC50 value (8 µM) in rat cortical neurons. |
|---|---|---|
| In Vivo | Safinamide mesylate (intraperitoneal injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.5097 mL | 12.5486 mL | 25.0973 mL | 50.1945 mL |
| 5mM | 0.5019 mL | 2.5097 mL | 5.0195 mL | 10.0389 mL |
| 10mM | 0.2510 mL | 1.2549 mL | 2.5097 mL | 5.0195 mL |
| 20mM | 0.1255 mL | 0.6274 mL | 1.2549 mL | 2.5097 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.